The oncologist
-
The prevalence of small cell lung cancer (SCLC) has declined in the U. S. as the prevalence of tobacco use has declined. However, a significant number of people in the U. ⋯ Rovalpituzumab tesirine, an antibody drug conjugate, has shown promising activity in patients with high delta-like protein 3 tumor expression (approximately 70% of patients with SCLC). The emergence of these and other promising agents has rekindled interest in drug development in SCLC. Several ongoing trials are investigating novel agents in the first-line, maintenance, and second-line settings.